Recall Record

East Brunswick, NJ, United States

Heritage Pharmaceuticals, Inc. recalls

10 recalls recorded since 2018, most recently on 30 July 2026. 2 are listed as ongoing. Status and classification are as published by the FDA.

Recalls10
Ongoing (FDA)2
Terminated or completed8
Class I (FDA)1

Ongoing Class II Drugs

Recall started
30 July 2026
Reason
Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.
Distribution
Nationwide within the U.S
Initiated
Voluntary: Firm initiated
Recall number
D-0768-2026

Ongoing Class II Drugs

Recall started
6 October 2025
Reason
CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.
Distribution
U.S. Nationwide.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0108-2026, D-0112-2026, D-0107-2026, D-0109-2026, D-0111-2026, D-0110-2026

Terminated Class II Drugs

Recall started
23 November 2022
Terminated
13 December 2023
Reason
Subpotent Drug
Distribution
Nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall number
D-0072-2023

Terminated Class III Drugs

Recall started
21 April 2021
Terminated
9 June 2022
Reason
Labeling: Incorrect or Missing Lot and/or Exp Date
Distribution
OH
Initiated
Voluntary: Firm initiated
Recall number
D-0367-2021

Terminated Class III Drugs

Recall started
23 October 2020
Terminated
28 January 2022
Reason
Failed impurities/ degradation specifications: Out of specification impurity results were observed during routine testing of stability samples for the impurity Felodipine Related compound A
Distribution
USA Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0108-2021

Terminated Class I Drugs

Recall started
21 May 2019
Terminated
11 January 2022
Reason
Non-Sterility:Microbial growth detected in sub lot of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) .
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-1398-2019, D-1397-2019

Terminated Class II Drugs

Recall started
3 May 2019
Terminated
16 November 2020
Reason
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
D-1288-2019, D-1289-2019, D-1291-2019, D-1290-2019, D-1287-2019

Terminated Class II Drugs

Recall started
15 February 2019
Terminated
4 March 2021
Reason
Subpotent Drug.
Distribution
Nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall number
D-1065-2019

Terminated Class II Drugs

Recall started
2 January 2019
Terminated
19 February 2021
Reason
Lack of Assurance of Sterility: complaints received about dried powder on the outside of bottle
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0352-2019

Terminated Class II Drugs

Recall started
15 October 2018
Terminated
29 March 2023
Reason
Lack of Assurance of Sterility: complaints received about dried powder on the outside of the bottle
Distribution
Nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall number
D-0094-2019

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.